AU Patent

AU2018201942B2 — Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan

Assigned to Ipsen Biopharm Ltd · Expires 2019-12-05 · 6y expired

What this patent protects

Abstract Provided are methods for treating pancreatic cancer in a patient by administering liposomal irinotecan (MM-398) alone or in combination with additional therapeutic agents. In one embodiment, the liposomal irinotecan (MM-398) is co-administered with 5-fluorouracil and leu…

USPTO Abstract

Abstract Provided are methods for treating pancreatic cancer in a patient by administering liposomal irinotecan (MM-398) alone or in combination with additional therapeutic agents. In one embodiment, the liposomal irinotecan (MM-398) is co-administered with 5-fluorouracil and leucovorin.

Drugs covered by this patent

Patent Metadata

Patent number
AU2018201942B2
Jurisdiction
AU
Classification
—
Expires
2019-12-05
Drug substance claim
No
Drug product claim
No
Assignee
Ipsen Biopharm Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.